The Global Health Innovative Technology (GHIT) Fund and United Nations-backed Medicines Patent have signed a Memorandum of Understanding (MOU) to strengthen the 30 October 2023
Tokyo-headquartered pharma major Takeda has announced results for the first half of its fiscal year, which in Japan runs from 1 April to 1 September. 27 October 2023
The TROPION-Lung01 Phase III trial has yielded positive data for datopotamab deruxtecan (Dato-DXd), an investigational TROP2-directed antibody drug conjugate (A 23 October 2023
Shanghai-based gene therapy company Belief BioMed (BBM) has out-licensed rights for the commercialization of its hemophilia candidate, BBM-H901, in China. 23 October 2023
At the annual congress of the European Society for Medical Oncology (ESMO), Seagen and Astellas Pharma have presented detailed data from the Phase III EV-302 st 23 October 2023